Complete Up To Date Information about Temaril-P Tablets.
NADA Number: 012-437 | |
| Proprietary Name |
Temaril-P® Tablets |
|---|---|
| Sponsor |
Pfizer, Inc. |
| Sponsor Address |
235 East 42d St. New York, NY 10017 USA |
| Ingredients |
Prednisolone Trimeprazine Tartrate |
| Species |
Dog, restricted during pregnancy |
| Routes of Administration |
Per Os |
| Dose Form |
Tablet |
| Drug Form |
Tablet |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.2604 Trimeprazine tartrate and prednisolone tablets. Specifications: Each tablet contains: trimeprazine tartrate, 5 milligrams; and prednisolone, 2 milligrams. Conditions of use: Dogs Amount: The drug is administered orally at an initial dosage level of 1/2 tablet twice daily to dogs weighing up to 10 pounds, one tablet twice daily to dogs weighing 11 to 20 pounds, two tablets twice daily to dogs weighing 21 to 40 pounds, and three tablets twice daily to dogs weighing over 40 pounds. After 4 days, the dosage is reduced to approximately 1/2 the initial dosage or to an amount just sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained. Indications: The drug is administered orally to dogs for the relief of itching regardless of cause; reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis and dermatitis, allergic, parasitic, pustular and nonspecific. It is also used in dogs as adjunctive therapy in various cough conditions including treatment of ``kennel cough'' or tracheobronchitis, bronchitis including allergic bronchitis in tonsillitis, acute upper respiratory infections and coughs of nonspecific origin. The product may also be administered to dogs suffering from acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents. Limitations: Do not use the drug in cases of viral infections involving corneal ulceration or dendritic ulceration of the cornea. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. NAS/NRC status: These conditions are NAS/NRC include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information. |
| Tolerances |
A tolerance of zero is established for residues of prednisolone in milk from dairy animals. |